Loading clinical trials...
Loading clinical trials...
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of QTX3046 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Conditions
Interventions
QTX3046
Cetuximab
Locations
5
United States
South Texas Accelerated Research Therapeutics, LLC Midwest
Grand Rapids, Michigan, United States
Duke Cancer Center
Durham, North Carolina, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
South Texas Accelerated Research Therapeutics, LLC San Antonio
San Antonio, Texas, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Start Date
May 30, 2024
Primary Completion Date
July 1, 2027
Completion Date
July 1, 2027
Last Updated
July 25, 2025
NCT06898450
NCT05720117
NCT05719558
NCT05098132
NCT07477743
NCT07029399
Lead Sponsor
Quanta Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions